Palantir Technologies Inc. (NYSE: PLTR) (“Palantir”) and Gemelli Generator Real World Data (RWD), a research facility of Fondazione Policlinico Universitario A. Gemelli IRCCS (“Policlinico Gemelli”), today announced a partnership to implement digital medicine research solutions that leverage artificial intelligence to improve patient care and health outcomes.
Policlinico Gemelli’s digital research center, Generator RWD, will utilize Palantir Foundry as one of the key enabling platforms to manage the full scale and complexity of healthcare data. Foundry’s AI capabilities will be utilized to generate Real World Evidence in support of clinical and translational research aimed at drug and indication discovery, improved patient care, and the development of digital medicine solutions for healthcare research in Italy and within their partnerships at global scale.
Palantir’s software will boost the capabilities of Generator RWD and its partner network as they continue in their quest to strengthen the exploitation of data to gain new insights in several healthcare research domains.
“Healthcare is transforming through the power of data and AI, and this trend will only accelerate. More and more of the industry is wielding this power to discover novel therapies, improve patient care and increase treatment efficiency and effectiveness,” said Andrea Galvagni, Head of Italy at Palantir. “At Palantir, we are proud to support world-leading institutions such as Policlinico Gemelli by providing them with the technology they need to achieve their most critical missions.”
“Real World Evidence is constantly gaining traction in support of research in healthcare. By integrating Foundry in the framework developed at Generator RWE, we aim at accelerating our research pipeline cycles to deliver faster and better outcomes,” said Vincenzo Valentini, Scientific Director of Gemelli Generator Research Facility.
“The added value of Palantir software and their deep skills in data-driven innovation will enrich the suite of products and services we are delivering within co-creation projects with our industrial partners,” said Alfredo Cesario, CEO of Gemelli Digital Medicine & Health.